Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients (3T Stroke-II)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 225 participants.

Also called NCT05281549

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 225 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05281549
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05281549. Randomized; single masking; primary purpose treatment. Start 2021-05-02 (actual); primary completion 2022-01-28 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients (3T Stroke-II)
Condition
Acute Ischemic Stroke
Intervention (Drug)
Alteplase
Intervention (Drug)
Tenecteplase
Intervention (Drug)
Tenecteplase
Lead sponsor
Beijing Tiantan Hospital (class: other)
Collaborator
Jiangsu FENG HUA Biotech Pharmaceutical Co., Ltd (class: not stated)
Collaborator
The Place Pharmaceutical(Jiangsu) Co., Ltd (class: not stated)

Record details

Record id
cardio:ct-nct05281549
Content hash
714699792cd5c5fe639f4202013d99d146a8580a18890a7d14443f7531a6bbbb